Chicago, IL, United States of America

Melina R Kibbe

This inventor holds 10 USPTO granted patents and 6 published patent applications and 2 EPO patents. Top assignees: Northwestern University, The University of North Carolina at Chapel Hill, Vesseltek Biomedical LLC. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Melina R Kibbe. Retrieved from https://idiyas.com/inventor/melina-r-kibbe

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 80.0

 

Average Co-Inventor Count = 2.5

ph-index = 3

Forward Citations = 39(Granted Patents)


Company Filing History:


Years Active: 2013-2025

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Melina R Kibbe - Pioneering Inventor from Chicago, IL

Introduction: Melina R Kibbe is a distinguished inventor based in Chicago, IL, known for her groundbreaking contributions to the field of medical innovations.

Latest Patents: Melina R Kibbe holds several patents in the medical technology sector, focusing on advancements in surgical techniques and medical devices.

Career Highlights: With a career spanning over two decades, Melina R Kibbe has held prominent positions in leading research institutions and universities, where she has spearheaded innovative projects in vascular surgery and biomedical engineering.

Collaborations: Throughout her career, Melina R Kibbe has collaborated with renowned medical professionals, researchers, and industry experts to develop cutting-edge solutions for complex medical challenges.

Conclusion: Melina R Kibbe's dedication to pushing the boundaries of medical innovation has solidified her reputation as a trailblazing inventor in the field of healthcare technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…